|
Anatomic Findings in AVNRT Patients with
supraventricular tachycardia and structurally normal hearts by echocardiography will undergo cardiac MRI and magnetic resonance venography of the coronary sinus prior to planned radiofrequency ablation in an effort to
evaluate the local anatomy of the AV node and coronary sinus os in the subgroup of patients who prove to have AVNRT.Investigator: Mehdi Razavi, MD (713)529-5530 WATCHMAN® Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) Patients with paroxysmal, persistent, or permanent atrial fibrillation and a CHADS2 score ¥ 1 will be randomized to either standard of care with chronic anticoagulation or
the percutaneous placement of a left atrial appendage occluder device. If the appendage is sealed after 45 days, patients will discontinue warfarin therapy unless otherwise indicated. Exclusion criteria include a recent
(within three months) stroke, transient ischemic attack, or myocardial infarction, a left ventricular ejection fraction < 30%, an existing pericardial effusion > 2 mm, planned pulmonary vein isolation or
cardioversion within 30 days, a resting heart rate > 110 bpm, the presence of a mechanical prosthetic valve, a contraindication to aspirin, an intracardiac thrombus by transesophageal echocardiography, or moderate
mitral stenosis (< 1.5 cm2).Investigator: Mehdi Razavi, MD (713)529-5530
Tailored Treatment of Permanent Atrial Fibrillation (TTOP-AF) Patients with permanent atrial fibrillation considered for an ablation procedure
will be randomized either to the Ablation Frontier ablation system or to optimal medical management. The inclusion criteria require symptomatic permanent atrial fibrillation (greater than seven days, but less than four
years, with at least one failed cardioversion within the previous two years, defined as the recurrence of atrial fibrillation within 30 days), as well as failure of rhythm control with at least one class I or III
antiarrhythmic agent. Exclusion criteria include left atrial dimension > 55 mm, pulmonary hypertension (PA pressure > 50 mm Hg), symptomatic heart failure (class III or IV), left ventricular ejection fraction <
40 %, moderate to severe mitral or aortic valve disease, stable or unstable angina, recent (within three months) myocardial infarction, prior ablation for atrial fibrillation, a history of stroke or transient ischemic
attack, or severe chronic obstructive pulmonary disease.Investigator: Abdi Rasekh, MD (713)529-5530 |
|
|
© 1998, 2000, 2002, 2003, 2004, 2005, 2006, 2007, 2008 by Hall-Garcia Cardiology Associates - Last revised March 12, 2008
Please contact our WebMaster with any questions or comments |
